After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price ...

Gilead pounced to buy cell therapy company Kite in August last year for just under $12 billion, shortly before the biotech firm gained approval for its CAR-T cancer therapy Yescarta. Now Gilead is ...

Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).

Gilead Sciences sets aside $200 million for a potential settlement over its HIV drug promotional speaker program amid federal ...

Gilead’s $11.9 billion purchase of Kite Pharma in 2017 didn’t follow the script, with two big write-downs in the value of the asset since then, but a fresh approval for a CAR-T therapy could ...

Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).

The cornea is the clear, outermost layer of the eye. Its outer border, the limbus, contains a large volume of healthy stem ...

Results from a Mass Eye and Ear-led phase 1/2 clinical trial of a novel stem cell treatment for cornea injuries found 14 ...

Amaris Balitsky reports research funding from Novartis; consulting fees from Sobi, BMS, and Kite/Gilead; and honoraria from BeiGene and Kite/Gilead. No other competing interests were declared.

A new stem cell therapy, CALEC, has demonstrated a 92% success rate in regenerating corneas and restoring vision. This ...